DKDimitra Kalavrizioti

Dimitra Kalavrizioti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dimitra Kalavrizioti has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    ERβ-Dependent Direct Suppression of Human and Murine Th17 Cells and Treatment of Established Central Nervous System Autoimmunity by a Neurosteroid

    by Maria Aggelakopoulou, Evangelia Kourepini, Nikolaos Paschalidis, Davina C. M. Simoes, Dimitra Kalavrizioti, Nikolaos Dimisianos, Panagiotis Papathanasopoulos, Athanasia Mouzaki, Vily Panoutsakopoulou

    Multiple sclerosis (MS), an autoimmune disease of the CNS, is mediated by autoreactive Th cells. A previous study showed that the neurosteroid dehydroepiandrosterone (DHEA), when administered preclinically, could suppress progression of relapsing-remitting experimental autoimmune encephalomyelitis (EAE). However, the effects of DHEA on human or murine pathogenic immune cells, such as Th17, were unknown. In addition, effects of this neurosteroid on symptomatic disease, as well as the receptors involved, had not been investigated. In this study, we show that DHEA suppressed peripheral responses from patients with MS and reversed established paralysis and CNS inflammation in four different EAE models, including the 2D2 TCR-transgenic mouse model. DHEA directly inhibited human and murine Th17 cells, inducing IL-10–producing regulatory T cells. Administration of DHEA in symptomatic mice induced regulatory CD4+ T cells that were suppressive in an IL-10–dependent manner. Expression of the estrogen receptor β by CD4+ T cells was necessary for DHEA-mediated EAE amelioration, as well as for direct downregulation of Th17 responses. TGF-β1 as well as aryl hydrocarbon receptor activation was necessary for the expansion of IL-10–producing T cells by DHEA. Thus, our studies demonstrate that compounds that inhibit pathogenic Th17 responses and expand functional regulatory cells could serve as therapeutic agents for autoimmune diseases, such as MS.


  • Open Access

    Cytokines as Biomarkers of Treatment Response to IFNβin Relapsing-Remitting Multiple Sclerosis

    by Nikolaos Dimisianos, Maria Rodi, Dimitra Kalavrizioti, Vasileios Georgiou, Panagiotis Papathanasopoulos, Athanasia Mouzaki

    Background. MS patients show a remarkable heterogeneity in their response to disease modifying treatments. Given the need for early treatment initiation and the diversity of available options, a predictive marker that indicates good or poor response to treatment is highly desirable.Objective. To find a biomarker for treatment response to IFNβamong pro- and anti-inflammatory cytokines.Materials and Methods. IFN-γ, TNF-α, IL-2, IL-4, IL-6, IL-10, IL-17A, and TGF-β1 levels were measured in serum and CSF of 43 patients with RR-MS who were followed up for a mean period of 5.3 years. Thirty-five patients received IFNβtreatment and were divided into good responders (GR,n= 19) and poor responders (PR,n= 16). The remaining 8 patients showed a very favorable outcome and remained untreated (noRx).Results. GR had significantly higher serum baseline levels of IL-17A than PR and significantly higher serum levels of IL-17A, IFN-γ, TNF-α, and IL-2 than noRx. PR had significantly higher IFN-γserum levels than noRx. No significant differences were observed in serum levels of IL-6, IL-4, IL-10, and TGF-β1 or the levels of all cytokines measured in CSF between the 3 groups of patients.Conclusions. Baseline serum levels of IL-17A can be used as a biomarker of IFNβtreatment response.


  • DRpp20 and DRpp40: Two protein subunits involved in Dictyostelium discoideum ribonuclease P holoenzyme assembly

    by Dimitra Kalavrizioti, Anastassios Vourekas, Denis Drainas